Core Viewpoint - The flu season in China has begun, leading to an increase in demand for antiviral medications, which has positively impacted the stock prices of related companies in the A-share market [1] Group 1: Market Overview - The flu activity level has significantly risen, with historical data indicating that the flu season typically starts in October to November, peaking around late December to early January [1] - E-commerce platforms report an increase in sales of antiviral medications for flu, reflecting heightened consumer demand [1] Group 2: Key Players and Supply Chain - Dongyang Sunshine Pharmaceutical holds a significant market share in the supply of Oseltamivir, a neuraminidase inhibitor, and has established a robust supply chain to ensure stable drug availability during peak flu seasons [2] - The company has comprehensive coverage across hospitals, chain pharmacies, and online platforms, maintaining sufficient inventory to meet market demands [2] Group 3: Antiviral Drug Developments - In the RNA polymerase inhibitor category, Marbofloxacin has gained traction due to its convenience as a single oral dose, marketed as "Xufuda" by Roche [3] - Roche has initiated local production of Xufuda in Shanghai to shorten supply chain times and enhance responsiveness to market needs [4] Group 4: Supply Assurance Measures - Roche has reported that the supply of Xufuda and Oseltamivir is stable across hospitals, with Xufuda's supply volume this year exceeding three times that of the previous year [5] - New RNA polymerase inhibitors have been launched by domestic companies, including Qingfeng Pharmaceutical's Marshulavavir, Zhongsheng Pharmaceutical's Anladiwei, and Jichuan Pharmaceutical's Maxilavavir, all of which are designed for adult treatment [5][6] Group 5: Distribution and Accessibility - Zhongsheng Pharmaceutical's Anladiwei is the first global RNA polymerase PB2 protein inhibitor for treating uncomplicated type A influenza in adults, with established distribution channels across major regions [6] - The company has a complete industrial chain system, ensuring quality and cost control of raw materials, and is actively adjusting production plans based on flu trends to meet demand [6]

流感特效药厂家众多。 当前，全国进入流感流行季，流感活动水平明显上升。 近日，中国疾病预防控制中心病毒病所研究员王大燕表示，监测数据显示，往年开始进入流感流行季的 时间一般都是在10—11月，个别年度也有9月份开始，流行高峰的时间一般出现在12月中下旬和1月初。 伴随着流感流行，流感药物需求增加。一些电商平台数据显示，流感抗病毒药物销量在增加。近两日， A股资本市场中的一些流感概念股股价也在上涨。抗流感特效药供应情况如何？ 我国目前上市的对流感病毒敏感的药物有神经氨酸酶抑制剂、RNA聚合酶抑制剂和血凝素抑制剂三 种，前两者应用较广，且对应的生产厂家较多。 在神经氨酸酶抑制剂方面，代表性药物是奥司他韦，主要有颗粒、胶囊、干悬混剂三大规格，可以覆盖 儿童以及成人患者。 长期以来，在奥司他韦供应上，东阳光药（06887.HK）占据较高的市场份额。 东阳光药物方面回复第一财经记者表示，流感由于需求的突发性，过往常出现市场供应短缺，终端价格 短期大幅波动的现象。作为国内该品类的主要供应商之一，公司已构建了成熟、完善的供应链体系与应 急预案，有能力在疫情高峰期确保药品的稳定供应，为满足市场需求、维护终端价格稳定提供坚实保 ...

每经AI快讯，东阳光药(06887.HK)早盘涨超3%，截至发稿，涨3.43%，报45.88港元，成交额454.31万港 元。 ...

消息面上，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物 的需求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资 料显示，东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦(商品名：可威)长期占据着国内 主要市场份额。 此外，11月25日晚，东阳光药发布公告称，公司有意于公开市场上购回自身股份。公司管理层对集团前 景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建 议回购符合公司与公司股东的整体最佳利益。 东阳光（600673）药(06887)早盘涨超4%，截至发稿，涨3.43%，报45.88港元，成交额454.31万港元。 ...

消息面上，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物 的需求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资 料显示，东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦（商品名：可威）长期占据着国 内主要市场份额。 智通财经APP获悉，东阳光药(06887)早盘涨超4%，截至发稿，涨3.43%，报45.88港元，成交额454.31万 港元。 此外，11月25日晚，东阳光药发布公告称，公司有意于公开市场上购回自身股份。公司管理层对集团前 景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建 议回购符合公司与公司股东的整体最佳利益。 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) intends to repurchase its own shares in the open market, reflecting the management's confidence in the company's long-term business prospects and development [1] Group 1 - The management team believes that the share repurchase proposal is in the best interest of both the company and its shareholders [1]

格隆汇11月25日丨东阳光药(06887.HK)公告，公司有意于公开市场上购回自身股份。公司管理层对集团 前景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为 建议回购符合公司与公司股东整体最佳利益。 ...

（股份代號：6887） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） 承董事會命 廣東東陽光藥業股份有限公司 董事長 張英俊博士 中國，東莞 自願公告 有意購回股份 本公告由廣東東陽光藥業股份有限公司（「本公司」）自願刊發。 本公司董事（「董事」）會（「董事會」）謹此宣佈，本公司有意於公開市場上購回（「建 議回購」）自身股份（「股份」）。本公司管理層對本集團前景充滿信心，而建議回購 體現了董事會及管理層團隊對本公司長遠業務前景及發展的信心。董事會認為建 議回購符合本公司與本公司股東（「股東」）之整體最佳利益。 截至本公告日期，本公司尚未根據《香港聯合交易所有限公司證券上市規則》（「上 市 規 則 」）第 10.06 條 獲 得 ...

Market Overview - The market consensus indicates a rebound from oversold conditions, with the Nasdaq rising 2.69% overnight, leading to a 0.69% increase in Hong Kong stocks at the close [1] US-China Relations - A surprising positive and constructive phone call occurred between US President Trump and Chinese President, discussing various topics including the Russia-Ukraine situation and agricultural products [2] - Trump has accepted an invitation to visit China in April next year, indicating a desire for improved relations ahead of the midterm elections [2] Lithium Industry - Longpan Technology announced a contract exceeding 450 billion yuan with subsidiaries, significantly surpassing the previous estimate of over 50 billion yuan, resulting in a nearly 23% surge in its stock [3] - Related companies such as Tianqi Lithium and Ganfeng Lithium also saw stock increases of nearly 5% and over 3%, respectively [3] AI Sector - Google aims to double its AI computing power every six months and achieve a 1000-fold increase in the next 4-5 years to meet rising demand [3] - Meta Platforms is reportedly considering a multi-billion dollar acquisition of Google's TPU for data center development, contributing to Google's stock rise of 6.31% [3] Hardware Sector - Changfei Optical Fiber's components business has become a strong growth point, benefiting from North American AI data center construction, with a stock increase of nearly 13% [4] - Baidu's revenue from Kunlun chips is expected to grow significantly, with projections showing a sixfold increase from 2025 to 2026 [4] Healthcare Sector - There has been a significant increase in flu antiviral drug purchases, with sales of certain medications rising over 14 times compared to October [6] - Companies like Alibaba Health and Shandong Xinhua Pharmaceutical saw stock increases of over 4% and 7%, respectively [6] Electric Vehicle Market - European electric vehicle sales surged, with plug-in hybrid sales up 40% and pure electric vehicles nearly 33% [7] - BYD's sales more than doubled, while other companies like NIO and XPeng are expanding into new markets [7] Huawei Product Launch - Huawei launched the Mate 80 series and Mate X7, showcasing significant performance improvements over previous models, which is expected to attract market interest [8] Zhongtong Express - Zhongtong Express reported strong growth in its parcel business, with a revenue increase of 11.1% year-on-year for Q3 2025 [9][10] - The company is expanding its operations with a new smart operations center and has implemented advanced delivery technologies to enhance efficiency [10]

Core Viewpoint - The demand for flu medications has surged as the country enters the flu season, leading to potential supply shortages and price volatility in the market [1] Group 1: Company Supply Chain and Market Strategy - Dongyang Sunshine Pharmaceutical, a major supplier of Oseltamivir, has established a mature and comprehensive supply chain system and emergency response plan to ensure stable drug supply during peak flu seasons [1] - The company has achieved full coverage of core terminals, including hospitals, chain pharmacies, and online platforms, while maintaining sufficient terminal inventory [1] - During the flu peak season, the company plans to collaborate with industry partners to meet medication needs across various market levels, providing stable and reliable drug support for public health [1] Group 2: Future Innovations and Strategic Goals - The company aims to leverage its R&D platform and strengths in the anti-infection field to innovate in flu treatment, utilizing AI pharmaceutical technology to accelerate the development of new products [1] - New pipeline products are expected to create synergies with Oseltamivir, enriching the pediatric anti-infection product lineup [1] - The company targets a strategic goal of reaching a scale of 10 billion in the anti-infection pediatric segment over the next 3-5 years, reinforcing its core competitiveness in flu treatment [1]